Cite
APA Citation
Zhang, L., Si, X., Wang, H., Zhang, X., Wang, M., Han, B., Li, K., Wang, Q., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Chen, W., Wang, X., Luo, Y., Nan, K., Jin, F., Li, B., & Chen, Y. (n.d.). 1390PDose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095484617.0x00002e